Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|September 2, 2013
- Pharmaceutical Technology-09-02-2013
- Volume 37
- Issue 9
Bosspak VTC 100 Tablet and Capsule Counter
The Bosspak VTC 100 electronic tablet and capsule counter from Romaco?s is designed to fill pharmaceutical solids or food supplements into bottles at high speed.
The Bosspak VTC 100 electronic tablet and capsule counter from Romaco is designed to fill pharmaceutical solids or food supplements into bottles at high speed. The machine works independently of particular formats, allowing the product and packaging to be changed quickly. The tablets, caplets, or gelatine capsules are fed to the counting stations by means of vibratory feed trays. The new sensor generation features built-in microprocessors that adjust the count trigger point automatically during production. The Bosspak VTC 100’s pre-dosing system can improve both counting accuracy and filling speed. The machine counts a maximum of 100 bottles a minute and can be installed either as a standalone unit or integrated in a line.
Articles in this issue
about 13 years ago
The Importance of Continued Investment in R&Dabout 13 years ago
FDA Works to Secure Drug Supply Chainabout 13 years ago
Outsourcing Partnerships for CMC Developmentabout 13 years ago
MF40 Automated Punch and Die Polishing Machineabout 13 years ago
Quality by Design in APIsabout 13 years ago
Connecting People, Science, and Regulationabout 13 years ago
Effective and Efficient Weighing of Potent Compoundsabout 13 years ago
EU Raises API Standards: A Curse in Disguise?about 13 years ago
The Importance of Characterization in Biosimilars Developmentabout 13 years ago
Omega Design Corporation Introduces LabelSync 450Related to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Complying with International Pharmacopoeias
3
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
4
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
5